Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 153

Results For "disease"

2674 News Found

No link between the use of ranitidine and cancer risk, claims Nature
News | February 24, 2023

No link between the use of ranitidine and cancer risk, claims Nature

N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.


AIIA Goa conducts induction programme for first batch of BAMS student
News | February 23, 2023

AIIA Goa conducts induction programme for first batch of BAMS student

Ayurveda is one of the most advanced sciences of its times


Thyrocare adopts SigTuple’s AI100 to make quality diagnostics accessible
Digitisation | February 22, 2023

Thyrocare adopts SigTuple’s AI100 to make quality diagnostics accessible

In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories


USFDA accepts biologics license application for Pfizer’s respiratory syncytial virus maternal vaccine candidate for priority review
Drug Approval | February 22, 2023

USFDA accepts biologics license application for Pfizer’s respiratory syncytial virus maternal vaccine candidate for priority review

This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency


Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio
News | February 22, 2023

Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio

The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies


New data confirm survival benefits of darolutamide in patients with metastatic hormone-sensitive prostate cancer
Clinical Trials | February 21, 2023

New data confirm survival benefits of darolutamide in patients with metastatic hormone-sensitive prostate cancer

New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)


Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions
Digitisation | February 20, 2023

Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions

Agasta Software is engaged in research, development and commercialization of medical devices


Fluor selected by Agilent for expansion of oligonucleotide manufacturing facility in Colorado
News | February 19, 2023

Fluor selected by Agilent for expansion of oligonucleotide manufacturing facility in Colorado

Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability


Pfizer announces Talzenna and Xtandi combination data from phase 3 study
News | February 18, 2023

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI


Merck and AstraZeneca present final results from Phase 3 PROpel Trial
Drug Approval | February 18, 2023

Merck and AstraZeneca present final results from Phase 3 PROpel Trial

Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival